Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity
- 1 August 2004
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 188 (2) , 292-299
- https://doi.org/10.1016/j.expneurol.2004.04.006
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Veterans Affairs
- Presbyterian Historical Society (HL41370, MH6410, NS14610)
This publication has 36 references indexed in Scilit:
- Neuronal Activity in Narcolepsy: Identification of Cataplexy-Related Cells in the Medial MedullaScience, 2006
- NarcolepsyCell, 2004
- The neurobiology, diagnosis, and treatment of narcolepsyAnnals of Neurology, 2003
- Neonatal glucocorticoids and the developing brain: short-term treatment with life-long consequences?Trends in Neurosciences, 2001
- Do immune cells promote the pathology of dystrophin-deficient myopathies?Neuromuscular Disorders, 2001
- Development of Cataplexy in Genetically Narcoleptic DobermansExperimental Neurology, 1998
- Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsyNeuroReport, 1996
- Fetal dexamethasone exposure interferes with establishment of cardiac noradrenergic innervation and sympathetic activityTeratology, 1993
- A Model of Methotrexate Encephalopathy: Neurotransmitter and Pathologic AbnormalitiesJournal of Child Neurology, 1986
- Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditionsJournal of the American Academy of Dermatology, 1982